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Summary 
Tumors engineered to express the costimulatory molecule B7-1  can elicit CD8 + cytotoxic T 
lymphocyte (CTL)-dependent  antitumor responses  in  immunocompetent mice.  It has been 
postulated that this result reflects direct priming of CTL by the modified tumor in vivo. Previ- 
ous studies of the immune response to a B7-1- murine colon carcinoma expressing influenza 
nucleoprotein (NP) as a model tumor antigen have demonstrated the crucial role of bone mar- 
row-derived antigen-presenting cells  (APCs)  in the priming of NP-specific CTL in vivo. In 
this system, no evidence of direct CTL priming by tumor was detected. We have performed a 
similar analysis  to determine if a B7-1 transfectant of this tumor results in the direct priming of 
CTL, and to compare this response to that primed by host APCs. When H-2b--~H-2  bxd bone 
marrow chimeras were immunized with a single injection of CT26/NP/B7-1  (H-2d), NP-spe- 
cific CTL were detected that were restricted to the bone marrow haplotype (H-2b), but not to 
the tumor haplotype. In contrast, CTL recognizing the NP antigenic epitope in the context of 
the tumor's major histocompatibility complex were detectable only after multiple immuniza- 
tions. These results suggest that whereas B7-1 + tumor vaccines result in some degree of direct 
presentation to CD8 + T  cells, the dominant mechanism of CTL priming is through the uptake 
and presentation of tumor antigens by bone marrow-derived APCs.  However, repeated im- 
munization  with  B7-1 §  tumor cells  can  efficiently expand  the  directly primed  CD8 §  CTL 
population. 
T  cell  activation requires  two  distinct  signaling  events 
(1-3).  The first signal originates from the binding  of 
the  TCI(  to  its  antigen-MHC  ligand,  and  provides  the 
specificity of the  interaction.  The  second  signal  is  either 
provided by soluble factors such as IL-2 or the interaction 
of cell surface molecules on the T  cell with their ligands on 
APCs. This second signal is thought to provide the neces- 
sary constimulation to the TCR.-mediated signaling event. 
Binding of the TCk  with peptide-MHC complexes in the 
absence of costimulation can result in T  cell inactivation or 
anergy, which is associated with a block in the IL-2 gene 
transcription (4-7). 
Among  the  known  costimulatory  molecules,  the  B7 
family of molecules appears to  be the  most potent.  Both 
B7-1  and  B7-2  can  interact  with  their  counterreceptor, 
CD28,  and  CTLA-4  on  T  cells.  Interaction with  CD28 
contributes to activation of helper T  cell  subsets and is im- 
portant for an intact in vivo immune response (8). The B7- 
CD28 interaction has also been shown to be necessary and 
sufficient costimulation for CD8 +  CTL generation in the 
absence of exogenous help  (4,  9).  Recently,  a number of 
experimental  systems  have  provided  evidence  suggesting 
the importance of both B7-1  and B7-2 as costimulators in- 
volved in generating antitumor immune responses (10-12). 
In some studies,  B7-1-expressing tumor cells are rejected 
in  syngeneic  hosts,  whereas  unmodified  B7-1-  parental 
tumors are not. These observations appear to vary depend- 
ing on the tumor system studied, with the greatest effect of 
B7-1  transfection occurring with more inherently immu- 
nogenic  tumors  (13).  In some of these  models, mice that 
successfully reject  the  B7-1  tumor  transfectants  as  a  live 
vaccine generate T  cell-mediated systemic immunity to the 
parental tumor. These studies suggest that tumors are capa- 
ble of delivering antigen-specific signals to T  cells, but may 
escape immunologic rejection by failure to deliver the co- 
stimulatory signals  necessary for the full activation of these 
tumor-specific T  cells.  The current working hypothesis is 
that B7-1 +  tumor cells  can provide both signals  one  and 
two directly to activate naive CTL in the absence of other 
bystander help. However, this hypothesis has not been for- 
mally tested, and in particular, the role of host APCs in the 
priming of antigen-specific CTL by the B7-1 + tumor cells 
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pression by tumor cells confers enhanced lysis by NK cells 
suggests  the  alternate mechanism of increased antigen re- 
lease and availability to host APCs in vivo. 
We have demonstrated that for certain tumors that orig- 
inated from "nonprofessional APCs" such as epithelial can- 
cers,  the priming of naive, tumor-specific CTL in vivo is 
mediated exclusively by the  host's  bone marrow-derived 
APCs (14).  In a series of in vivo and in vitro experiments 
with parent-into-F1 bone marrow chimeras, we have shown 
that  a  tumor lacking the  appropriate  costimulatory mole- 
cules could not directly activate CTL, but did so indirectly 
by  shedding  tumor  antigens for  uptake,  processing,  and 
presentation by professional APCs, a phenomenon termed 
"cross-priming" (15,  16).  In the present study, we employ 
the same bone marrow chimera system to assess the role of 
B7-1 +  tumor cells relative to  the  host APC  in mediating 
the  priming  of  tumor-specific,  MHC  class  I-restricted, 
CD8 +  CTL.  We  have  found that  whereas  B7-1 +  tumor 
cells  are  capable  of directly priming naive  CTL  in vivo, 
they do so much less efficiently than host APCs. The data 
demonstrate that whereas some direct presentation capacity 
is indeed conferred by B7-1  expression, most of the CTL 
priming is  related to  other mechanisms, such as increased 
lysis of B7-1 + tumors in vivo, which facilitates subsequent 
antigen uptake and processing by professional APCs. 
Materials  and Methods 
Mice.  6-8-wk-old female C57BL/6 (H-2b), BALB/c (H-2d), 
and their F  1 progeny CB6Fm (H-2  bxa) were  obtained from the 
National Institutes of Health  (Frederick,  MD).  Parent-into-F1 
bone marrow chimera mice were created as described previously 
(14) and are summarized below. 
Cell Lines and Clones.  CT26  is  a  moderately  immunogenic 
colonic epithelial tumor derived from the BALB/c mice. CT26NP 
was derived by infecting CT26 with a Moloney-based defective 
recombinant retrovirus  encoding both the  nucleoprotein (NP) 1 
gene of the PR8 influenza strain and a neomycin-resistance  gene 
(Neo)  (14, 17). Cotransfection of CT26NP with plasmids encod- 
ing the  hB7-1  and a hygromycin-selectable marker resulted  in 
CT26NPB7 lines. The transduced and transfected  cell lines were 
cloned by limiting dilution cloning in selecting media.  The re- 
sulting clones of CT26NP and CT26NPB7 were stained for the 
level of NP (mAb HB65)  and B7 (CTLA4-Ig), and tested as tar- 
gets for lysis by a NP-specific, H-2d-restricted CTL line. Intracel- 
lular NP staining was performed first by permeabilizing cells with 
70% ice-cold ethanol, followed by incubation with NP-specific 
mAb  HB65  at  4~  for  30  min.  FITC-labeled secondary goat 
anti-mouse IgG  (Southern Biotechnology Associates, Birming- 
ham, AL) was then added at 4~  for 30 min. Surface B7-1 stain- 
ing was performed by first adding CTLA4-Ig at 4~  for 18 rain, 
followed  by  FITC-labeled  secondary  goat  anti-human  IgG 
(Southern  Biotechnology  Associates)  at  4~  for  18  min.  A 
CT26NP clone and a CT26NPB7 clone positive for both anti- 
body staining and CTL lysis were chosen for further experiments. 
CT26NP  and CT26NPB7  clones  exhibited similar  patterns of 
1Abbreviation used in this paper: NP, influenza  nucleoprotein. 
growth kinetics compared to that of CT26WT both in vitro as 
well as in SCID mice. Whereas CT26 and CT26NP showed sim- 
ilar growth kinetics in intact BALB/c and CB6F  1 mice (100% tu- 
mor incidence in 3 wk when injected with 106 live tumors),  mice 
injected with live CT26NPB7 clone showed slowing of tumor 
growth with complete rejection in 20% of animals at 106 cell dose 
and 80% of animals at 2.5  ￿  105 cell dose). 
Synthetic NP Nanomeric Peptides.  The  immunodominant  na- 
homeric H-2Ka-restricted NP(147-155)  peptide  (TYQRTRALV) 
and  H-2Db-restricted  NP(366-374)  peptide  (ASNENMETM) 
were  synthesized  by the  Protein/Peptide/DNA Facility  at  the 
Johns Hopkins University School  of Medicine. The  sequences 
were confirmed by amino acid analysis and mass spectrometry. 
Construction of Bone Marrow Chimera Mice.  The  parent-into-F~ 
bone marrow chimeria mice were constructed as described previ- 
ously (14). Briefly, recipient female CB6F 1 mice were depleted of 
NKI.1 + cells with mAb, PK136 (American Type Culture Col- 
lection, Rockville, MD),  1 d before and after the marrow trans- 
plant to avoid the Hh rejection phenomenon. On the day of the 
transplant, donor bone marrows were harvested from both the fe- 
mur and the tibia of the C57BL/6, BALB/c, and CB6F1 mice. 
The resultant bone marrow cells were depleted of mature T cells 
by treatment with mAb RL172  (anti-CD4), 3-155  (anti-CD8), 
J1J (anti-Thyl), C3PO (anti-CD5; American Type Culture Col- 
lection), and rabbit complement (Low-Tox M; Cedarlane, Accu- 
rate  Chemical and Scientific  Corp., Westbury, NY). 2-5  ￿  10  ~' 
of the T  cell-depleted bone marrow cells were injected inn'ave- 
nously into  lethally  irradiated  (10  Gy)  CB6F1 recipients.  The 
control mice received injection of saline alone and expired be- 
tween days 12 and 21  after transplant.  5 mo after the transplant, 
representative  chimera mice were  killed.  Splenocytes  from  the 
chimeras were stained with haplotype-specific,  anti-MHC class I1 
mAb Y3P  (anti-I-A  b)  and  14.4.4  (anti-I-E  a)  followed by goat 
anti-mouse IgG2a-FITC  (Southern Biotechnology Associates), 
and analyzed by FACScan  |  (Becton Dickinson & Co., Braintree, 
MA) to confirm complete bone marrow reconstitution. 
In  Vivolmmunization.  CT26,  CT26NP,  and  CT26NPB7 
were harvested  and washed in HBSS three times. Before  immu- 
nization, samples of the different  cell lines were analyzed on the 
FACScan  |  for the level of NP and B7-I expression. Two to five 
mice from each of the chimera groups (H-2b---)H-2b￿  H-2d--->H  - 
2bxd; and H-2bxa-->H-26￿  received 106 cells of live or irradiated 
(50 Gy) CT26, CT26NP, or CT26NPB7 subcutaneously in the 
left flank. 2 wk later, mice were either reimmunized with a sec- 
ond dose of tumor cells, or were killed for subsequent secondary 
in vitro stimulation and chromium release assays. 
Secondary  In  Vitro  Stimulation  and  Chromium  Release  Assay. 
Splenocytes were harvested from immunized chimeric mice 2 wk 
after either the first or the second dose of immunization. A frac- 
tion of the splenocytes  from each  chimera was analyzed on the 
FACScan  |  to test for the presence  of any contaminating residual 
H-2  t'Xa APC using haplotype-specific  anti-MHC class II antibod- 
ies. In all cases, the level of detectable  staining with antibody rec- 
ognizing the opposite haplotype as compared to the bone marrow 
was the same as that of the background staining with secondary 
FITC-labeled antibody alone.  A portion of the splenocytes  from 
each mouse was incubated either with NP(147-155) or NP(366- 
374) peptides  in the presence  of live CB6F I (H-2  bxd) splenocytes 
and IL-2. After 7 d, responder cells were harvested,  washed,  and 
incubated with  chromium-51  (30  mCi/ml; Amersham  Corp., 
Arlington Heights,  IL)-labeled surrogate target cells, P815  (H-2  d) 
or MC57G (H-2b), pulsed with either NP(147-155) or NP(366- 
374) peptides. After a 4-5-h incubation at 37~  and 5% CO,, su- 
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The percent specific lysis =  100% ￿  (sample cpm -  spontaneous 
cpm)/(maximum cpm -  spontaneous cprn). The percent peptide 
specific lysis was the difference  between the percent specific lysis 
of the  target  cells pulsed  with  the MHC-matched peptide  and 
that with the MHC-mismatched peptide. 
Results 
Characterization  of Tumor Constructs.  We  have  devel- 
oped  clones  of CT26  that  express  the  viral  protein,  NP, 
with or without the expression  of the costimulatory mole- 
cule,  B7-1.  (Fig.  1  A).  Both  CT26NP  and  CT26NPB7 
clones exhibited similar in vitro as well  as in vivo growth 
kinetics in SCID mice compared to that of the parental tu- 
mor,  CT26  (data  not  shown).  The  NP-expressing  tumor 
clones were also recognized as targets in an in vitro chro- 
mium release  assay by H-2Ka-restricted,  NP-specific CTL 
lines generated from infection of BALB/c mice with a sub- 
lethal dose of the PR.8 strain of influenza  (Fig.  1 B). Mice 
immunized with irradiated  CT26NP or CT26NPB7 were 
able to elicit a CTL response recognizing a surrogate target 
pulsed  with  the  NP nanomeric  peptide  in vitro.  Further- 
more, mice infected with a sublethal dose of PR8 strain of 
influenza  were  able  to  reject  a  live  CT26NP  challenge, 
whereas mice chal/enged with parental  CT26 failed to re- 
ject the inoculation (data not shown). Taken together, NP 
represents  a good model tumor antigen since  (a)  the pres- 
ence  of the  viral  antigen  did  not alter  the  tumorigenicity 
and immunogenicity of CT26;  (b)  the  NP antigen is pre- 
sented by the two different tumor clones at levels recogniz- 
able by NP-specific,  MHC  class  I-restricted  CTL;  and  (c) 
CT26NP was able to be rejected in a NP-specific manner 
in mice previously immunized against the antigen.  Similar 
to  other  investigators'  observations,  CT26NPB7  injected 
subcutaneously can be rejected in a CD8-dependent  man- 
ner  (20--80% rejection  depending  on the  challenge  dose). 
Tumor explants from mice that failed to reject the primary 
CT26NPB7  challenge showed a decreased level of B7 ex- 
pression, but retained NP expression as determined by their 
ability to be lysed by NP-specific CTL in vitro. 
Comparison  of In  Vivo  CTL Priming by  Tumor Cells  versus 
Host APCs.  Analysis of the specificity of anti-NP CTL in 
parent--)F 1 chimeras  immunized  with  NP-transfected  tu- 
mors allows the direct assessment of presentation by the tu- 
mor versus host bone marrow-derived cells.  This is because 
the bone marrow-derived cells and tumor cells can express 
different MHC  class I alleles  and thus will present different 
epitopes  of NP.  When  H-2b--)H-2  b~d bone  marrow  chi- 
meric  mice  were  initially  immunized  with  irradiated 
CT26NPB7  (H-2d),  no  detectable  CTL  activity was  ob- 
served  against  H-2  a targets  pulsed  with  the  NP(147-155) 
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Figure 1.  Expression of NP and B7-1 in various CT26 constructs. (/1) parental CT26, CT26NP, and CT26NPB7 are stained with either mAb HB6.5 
(Anti-NP, intracel/ular) or CTLA4-lg (anti-B7, surface), followed by FITC-tabeled goat anf~-mouse lgG (HB6.5) or goat anti-human IgG (CTLA4-Ig) 
(solid lines). As controls, each cell construct was stained with FITC-labeled secondary  antibody alone (broken lines). (B) CT26 (closed circles), CT26NP (open 
squares), and CT26NPB7 (~pen triangles) were labeled with 51Cr and used in an in vitro chromium release assay as targets against CTL hnes generated from 
mice infected with the PR8 strain of  influenza. CD8-blockable lysis (%) was the difference between percent specific  lysis with and without the presence 
ofmAb 2.43 (anti-CD8). Non-CD8-blockade lysis never exceeded 5% at a 100:1 E/T ratio. 
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the tumor cell had occurred, or that the frequency of H-2  d- 
restricted CTL was below the sensitivity of the in vitro as- 
say  (Fig.  2  A).  As  described  previously,  mice immunized 
with CT26NP or CT26 also failed to generate CTL against 
NP in the context of the tumor's MHC. In contrast, H-2  a- 
restricted  CTL  were  generated  when  H-2d-oH-2  bxd  or 
H-2bxd--)H-2  bxd  chimeras  were  immunized  with  either 
CT26NP  or CT2NPB7  (Table  1).  CTL which recognize 
the  H-2  b  targets  pulsed  with  the  NP(366-374)  peptide 
were  observed when  H-2b--~H-2  bxd  chimeric  mice were 
immunized with either CT26NP or CT26NPB7, indicat- 
ing that  anti-NP  CTL were primed  in vivo by the bone 
marrow-derived APCs (Fig. 2  B and Table  1).  These data 
suggest  that  whereas  CT26NPB7  fails  to  directly  prime 
CTL in vivo to levels above the assay's detection limit, the 
cross-priming  pathway  results  in  readily  measurable  CTL 
activity. 
To  increase  the  ability  to  detect  low  levels  of direct 
priming by CT26NPB7,  mice were immunized  and then 
boosted 2 wk later.  Reimmunization of the H-2b---)H-2  bxd 
chimera  with  irradiated  CT26NPB7  resulted  in  NP-spe- 
cific CTL restricted by H-2  b, as was seen after a single vac- 
cination  (Fig.  3  B and Table  1).  However, with boosting, 
H-2d-restricted,  anti-NP  CTL were also  observed  (Fig.  3 
A). This is in sharp contrast to similar chimeras immunized 
with CT26NP alone, in which the H-2d-restrictd, anti-NP 
CTL were  never  detected,  even  after boosting  (Fig.  3  A 
and  Table  1).  Table  1  summarizes  the  results  of experi- 
ments  using different  chimeras  constructs,  cell clones,  and 
immunization dosing schedules. 
The  lower  efificiency of CTL  priming  by CT26NPB7 
compared to that by host APC may be due to the effects of 
irradiation  on the  vaccinating cells.  Although the  mecha- 
nism is not well understood, it has been shown that irradi- 
ating BT-l-transfected tumor cells may diminish the ability 
to generate systemic antitumor immunity (18). This may be 
the reason why direct tumor priming was observed only after 
multiple vaccinations with irradiated CT26NPB7, whereas 
cross-priming was detected after a single immunization. To 
test  this  hypothesis,  Ht-2b-->H-2  bxd  chimeras  were  immu- 
nized  with  either  irradiated  or live  CT26NPB7,  and  the 
splenocytes were analyzed 2 wk later. As stated above, 20- 
80% of mice injected with live CT26NPB7  can reject the 
tumor.  To eliminate  the confounding issue of tumor bur- 
den on the immune  response,  only the mice that rejected 
the primary tumor challenge were used for this assay. Fig. 5 
shows the  result  of such  experiments.  The  H-2b-->H-2  bxd 
chimera immunized with live CT26NPB7 failed to gener- 
ate detectable levels of H-2a-restricted (Fig. 5), NP-specific 
CTL, even though CTL were generated that recognize NP 
in the H-2  b haplotype (data not shown). These data suggest 
that  the  cross-priming pathway  is  dominant  over the  di- 
rect-priming  pathway,  regardless  of whether  immunizing 
tumor cells were irradiated or live. 
Lack of Residual Radio-resistant  H-2 bxa APCs  in the H-2b--)H - 
2 b~a Chimeras.  Whereas  the  appearance  of  the  H-2  d- 
restricted,  anti-NP  CTL  in  the  H-2b--)H-2  bxd  chimeras 
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Figure  2.  Epitope  specificity of T cells from H-2b--)H-2 bxd chimera 
mice immunized once with various tumor constructs. Mice were immu- 
nized once with either CT26  (closed circles), CT26NP  (open squares), or 
CT26NPB7 (open triangle). 2 wk later, splenocytes  from these mice were 
then stimulated with either NP(147-155) (top) or NP(366-374) (bottom) 
+ H-2  bxa splenocytes. Cells were then mixed with 51Cr-labeled P815 tar- 
gets and NP(147-155) (H-2  a, top) or MC57G targets and NP(366-374) 
(H-2  s, bottom). Peptide-specific lysis represents the difference between the 
percent specific lysis of the target cells with the MHC-matched NP pep- 
tide and the percent specific lysis of the target cells with the MHC- 
mismatched peptide. In all cases, lysis of targets in the presence of the 
MHC-mismatched NP peptide was <5% at all E/T ratios. Data are rep- 
resentative of three separate experiments. 
immunized twice with CT26NPB7 may reflect direct prim- 
ing of naive  CTL in vivo,  it  is  possible  that  CT26NPB7 
cannot directly initiate the priming of CTL, per se, but can 
amplify,  in  the  subsequent  immunization,  the  activated 
CTL precursors  that were  initially  primed  by residual  ra- 
dio-resistant I-I-2  bxa APCs. The precursor frequency of such 
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CT26  Lysis against* 
Chimera  (MHC)  NP  B7  (MHC)  Vaccine no.  P815 +NP  (H-2  a)  MC57G + NP(H-2 b) 
a  CB6F1-->CB6F  1 
b  CB6F1-->CB6F  1 
c  CB6F1--~CB6F  1 
d  CB6F1--)CB6F  1 
e  CB6F1--~CB6F  1 
f  CB6F~--)CB6F  1 
g  C57BL/6---)CB6F 
h  C57BL/6-->CB6F 
i  C57BL/6--)CB6F 
j  C57BL/6--~CB6F 
k  C57BL/6--)CB6F 
1  C57BL/6--)CB6F 
rn  BALB/c--~CB6F~ 
n  BALB/c-->CB6F  1 
o  BALB/c-->CB6F  1 
p  BALB/c--)CB6F1 
q  BALB/c--~CB6F1 
r  BALB/c---)CB6F  1 
b/d---)b/d  -  -  d  1  -  - 
b/d--ob/d  +  -  d  1  +  + + 
b/d---)b/d  +  +  d  1  + + +  + + + 
b/d-->b/d  -  -  d  2  -  - 
b/d---)b/d  +  -  d  2  + + +  + + + 
b/d---)b/d  +  +  d  2  +  + + 
b-->b/d  -  -  d  1  -  - 
b--)b/d  +  -  d  1  -  + + 
b---)b/d  +  +  d  1  -  + + 
b--->b/d  -  -  d  2  -  - 
b--)b/d  +  -  d  2  -  + + + 
b-->b/d  +  +  d  2  + + +  + + 
d--->b/d  -  -  d  1  -  - 
d---)b/d  +  -  d  1  +  - 
d----)b/d  +  +  d  1  + +  - 
d---~b/d  -  -  d  2  -  - 
d--)b/d  +  -  d  2  + +  - 
d---)b/d  +  +  d  2  + + +  - 
Different bone marrow chimeras and tumor constructs were used. H-2bxa-->H-2  bxa chimera (a-J), H-2b--)H-2  bxa (g-/) chimera,  or H-2a--~H-2  b~a (m-r) 
chimera were immunized with different irradiated  tumor constructs.  The magnitudes of the epitope-specific CTL against P815+NP(147-155)  target 
or MC57G+NP(366-374)  target are indicated by the plus (+) signs. 
*At a 100:1 E/T ratio:  -  (5%), +  (10%), ++  (20%), +++  (<30%),  ++++  (<40%),  +++++  (>40%). 
CTL  may have been too low after the initial immunization 
to be  detected in  the in vitro CTL  assays.  To  address  this 
latter possibility,  we  first  sought  to  detect  residual  H-2  bxd 
APCs in the chimeras by FACScan  |  (Becton Dickinson & 
Co.)  as well as in  two  functional  assays.  Splenocytes  from 
each  experimental  chimera  were  stained  with  haplotype- 
specific antibody and analyzed on a  FACScan  |  In no case 
was  there  any  detectable  level  of  contaminating  H-2  bxa 
APC  detected  (sensitivity  to  <2%)  5  mo  after  the  bone 
marrow reconstitution.  Detection of residual H-2 bxd APCs 
in the H-2b-->H-2 bxd chimeras was further sought in an al- 
logeneic  mixed  lymphocyte  reaction  (data  not  shown). 
Stimulation  of C57BL/6  splenocytes with APCs  from  the 
H-2b--)H-2 bxd  chimeras  gave  levels  of  proliferation  no 
greater than the autologous mixed lymphocyte reaction.  In 
contrast,  C57BL/6  splenocytes  proliferated  vigorously  in 
the  presence  of splenocytes  from  either  H-2bxd-->H-2  bxd 
chimeras,  BALB/c,  or  C57BL/6  mixed  with  50,  25,  10, 
and 0.5% of H-2 b~a splenocytes. 
To  further  exclude  the possibility that  CT26NPB7  acts 
to  amplify H-2d-restricted,  anti-NP  CTL  previously acti- 
vated  by  residual  host  H-2 bxd APCs,  a  double  immuniza- 
tion  experiment  was  performed.  H-2b--~H-2  bxd  chimera 
mice were  first  immunized  with  irradiated  CT26NP,  and 
reimmunized 2  wk later with irradiated CT26NPB7.  If the 
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primary  induction  was  mediated  by  the  host's  residual 
APCs,  then  it  should  not  matter  whether  mice  were  ini- 
tiaUy immunized with CT26NP  or CT26NPB7,  as long as 
CT26NPB7  was  used  in  the  subsequent  immunization. 
Fig.  4  demonstrates  that  anti-NP,  H-2d-restricted  CTL 
were  observed  only in  the  case where  the  chimeras  were 
inununized  sequentially  with  two  doses  of  irradiated 
CT26NPB7.  Mice immunized either with two doses of ir- 
radiated  CT26NP  or one  dose  of irradiated  CT26NP  fol- 
lowed by a dose of CT26NPB7  failed to generate apprecia- 
ble levels of H-2d-restricted,  NP-specific CTL activity. 
Discussion 
Several  studies  have  explored  the  use  of B7-1-trans- 
fected tumor cells as a strategy for generating systemic anti- 
tumor  immunity.  Using a  melanoma  cell hne,  Townsend 
and Allison (11)  observed that mice successfully rejected an 
innoculum  of live  B7-1 +  melanoma.  In  a  related  study, 
Chen  et al.  (10)  reported that  rejection of a  murine  mela- 
noma line required the expression of B7-1  as well as a  for- 
eign antigen,  HPV-16  E7. In both of these studies,  the pri- 
mary  rejection  of the  tumor  cells  resulted  in  long-term 
protection against a secondary challenge with the B7-  neg- 
ative parental tumor, as well as eradication ofpreestablished P815  (H-2  d  )  +  NP(147-15S)  target  P815  (H-2  d  )  +  NP(147-1SS)  target 
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Figure 3.  Epitope  specificity of T cells from H-2b----)H-2  bxd chimera 
mice immunized  twice with various tumor constructs. Mice were immu- 
nized twice 2 wk apart with either CT26 (closed circles), CT26NP (open 
squares),  or CT26NPB7 (open  triangles). 2 wk after the second immuniza- 
tion, splenocytes  were removed and analyzed  under the same condition as 
described in the legend to Fig. 2. The results are representative of three 
separate experiments. 
micrometastases.  Tumor  rejection  was  shown  to  require 
CD8 § but not CD4 + T  cells, since depletion of the former 
rendered mice tumor prone. The failure to demonstrate a 
requirement for CD4 + T  cells in this system is supported 
by earlier studies (4) demonstrating CD4-independent  prim- 
ing of CTL when TCR  engagement is  accompanied by 
B7-1-mediated cross-hnking of CD28.  Baskar  et  al.  (19) 
have subsequently reported that CD4 + T  cells play a criti- 
cal role in the  rejection of tumors cotransfected with the 
genes  encoding MHC  class  II  antigen  as  well  as  B7-1, 
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Figure 4.  Direct  priming  ofNP-specific CTL by B7 + tumor and the role 
of residual H-2  bxd APCs in priming such CTL. H-2b-oH-2 bxd chimera 
mice were immunized either twice with CT26 (closed circles), CT26NP 
(open  circles), or CT26NPB7 (open  triangles),  or once with CT26NP fol- 
lowed by one injection of CT26NPB7 (closed squares). 2 wk after the last 
injection, splenocytes  were analyzed  as described in the legend to Fig. 2. 
Only the H-2  a epitope specificity is shown. Closed circles and closed 
squares are superimposed. 
which also resulted in generation of potent systemic immu- 
nity against the nontransfected parental tumor. 
It has  been postulated that  tumor-specific CD8 +  CTL 
are primed directly by the B7-1-transfected tumor which 
provides both signals 1 and 2 to the CTL precursor (6).  In 
contrast to the tumor cells acting as APCs, we have previ- 
ously reported that host bone marrow-derived professional 
APCs are the dominant cell population mediating tumor- 
specific CTL priming. Using parent-into-F  t bone marrow 
chimeras in which the haplotype of the reconstituted APC 
population is distinct from that of the tumor, we have con- 
sistently found that B7-1-, MHC  class  I-  tumors cannot 
prime tumor-specific, CD8 +, MHC class I-restricted CTL 
in  vivo.  Rather,  the  host  bone  marrow-derived  profes- 
sional APCs are the  exclusive APCs in priming the naive 
CTL through  a  MHC  class  1-processing and -presenting 
pathway for exogenous tumor antigens. 
The current study extends these observations to examine 
the role orB7-1 + tumor cells in generating an antitumor im- 
mune response. Mice immunized  with irradiated CT26NPB7 
were found to have detectable NP-specific CTL restricted 
to the haplotype of the tumor, but only after multiple im- 
munizations. In contrast, NP-specific CTL restricted to the 
haplotype of the bone marrow were easily detected after a 
single  immunization.  These  results  indicate  that  B7-1- 
transfected tumor can directly serve as APC for the priming 
of naive CTL in vivo, but the efficiency of this process is 
far less than that of CTL priming by the host's professional 
APCs. If the cross-printing pathway is so potent and B7-1 + 
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Figure 5.  Epitope specificity ofT cells from H-2b-~H-2  bxa immunized 
with either live (open circles) or irradiated (open triangles) CT26NPB7. As a 
control, H-2bxa--~H-2  bxa chimeras were injected with  live CT26NPB7 
(open squares). Mice were killed 2 wk after the immunization, and their 
splenocytes were analyzed as described. 
tumor  cells  do  not  efficiently  prime  naive  CTL  in  vivo, 
why  then  should  there  be  an  enhanced  immunogenicity 
seen with B7-1 + tumors?  One  possible explanation  is that 
B7-1  expression on the tumor cell makes the cell more sus- 
ceptible to lysis in vivo. Several studies (20-22) suggest that 
B7-1  may enhance  the susceptibility of the tumor to CTL 
killing.  In one model system, the in vivo killing of B7-1 + 
tumors was shown to be dependent  on both NKI.1 + cells 
and CD8 + T  cells (22).  The enhanced  immunogenicity  of 
the  B7-1 +  tumor may be  caused  by the  increased  lysis  of 
the  tumor cells,  thus  releasing  more antigens  available for 
the  cross-priming pathway.  Our cross-priming experiment 
with live CT26NPB7  tumor cells supports  this  hypothesis 
(Fig. 5). The injected live CT26NPB7  tumor cells were re- 
jected,  even though  antigen-specific  CTL restricted  to the 
tumor's MHC  class I cannot be demonstrated in vitro.  On 
the  other  hand,  NP-specific  CTL  primed  by  the  host's 
APCs can be readily detected.  This may explain earlier ob- 
servations indicating that the ability of B7-l-transfected  tu- 
mor vaccines to generate effective systemic immunity is de- 
pendent  on  the  inherent  immunogenicity  of the  parental 
tumor  (13).  Immunogenic  tumors  transfected  with  B7-1 
that  are lysed in vivo by CTL  or NK  cells would  release 
antigens  in  a  form  that  is  efficiently  processed  by  host 
APCs; this would lead to systemic immunity to the parental 
tumor. B7-1  transfection  of nonimmunogenic  tumors may 
result in the  elimination  of the  transfected population,  but 
generate little systemic immunity. This issue cannot be pre- 
cisely  addressed  in  the  present  study,  and  awaits  further 
analysis. 
It has  been  recently  shown  that  the  microenvironment 
greatly influences the ability to prime MHC  class I-restric- 
ted CTL to tumor cell antigens.  Using a fibrosarcoma cell 
line and different model tumor antigens,  Kundig et al.  (23) 
have shown  that this  tumor,  which  fails  to express known 
costimulatory molecules or cytokines, is capable of directly 
priming  and  activating  tumor-specific  CTL  in  vivo,  but 
only in the environment of a lymphoid organ.  Intraperito- 
neal  injection  was  found  to  result  in  lymphoid  metastases 
and  direct  CTL priming,  whereas  subcutaneous  injection, 
as was the case in our current report, did not result in direct 
CTL priming. Given the well-demonstrated ability ofpara- 
crine cytokine stimulation,  such as by IL-2, to provide co- 
stimulation  for CTL generation,  this result is not inconsis- 
tent  with  the  two-signal  model  for T  cell  activation,  and 
generally  supports  our findings  of the  inability  of nonhe- 
matopoietic  tumors  to directly prime naive CTL in situ  at 
their site of origin,  or at a subcutaneous  vaccination site.  It 
does  raise  the  following  question,  however:  why  are  so 
many solid  tumors  present  clinically  with  early stage  dis- 
ease,  with  lymph  node  invasion  as  the  only  site  of mi- 
crometastases,  if in  fact  this  microenvironment  efficiently 
promotes  tumor-specific  CTL  generation?  In  contrast  to 
our  observations,  these  authors  (23)  failed  to  observe  any 
cross-priming by host APCs.  The reason for this difference 
is unclear,  but it is likely to involve features of the  tumor 
models that affect the  efficiency of exogenous  antigen  up- 
take and processing by APCs.  Given the incompletely un- 
derstood pathways of antigen  trafficking for cross-priming, 
the explanation of this discrepancy awaits further study. 
In conclusion,  we have examined the ability of a B7-1 +, 
MHC  class  1 +,  MHC  class  II-  colonic  carcinoma  to  di- 
rectly mediate  the  induction  and  activation  of tumor-spe- 
cific CTL in vivo. Contrary to the current working model 
of immune activation by B7-1 +  tumor,  the primary route 
of antitumor induction  does not appear to be through  the 
tumor cells,  but via the  host's hematopoietic-derived  pro- 
fessional APCs.  The in vivo pathways for exogenous  anti- 
gen  uptake,  processing,  and  presentation  on  MHC  class  I 
molecules are under active investigation. 
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